AdvaMed Statement on President’s Reciprocal Tariff Pause
WASHINGTON – Today AdvaMed, the Medtech Association, released the following statement from President and CEO Scott Whitaker:
“We are encouraged by the President’s announcement of a 90-day pause on reciprocal tariffs. This is an important decision that restores some short-term certainty to global markets, including the American medtech industry, which is number one globally.
“Moving forward, we will spend the next 90 days working with the President and his senior team to ensure the unique role of the medtech industry is protected, with the hope that the ultimate outcome is ‘zero for zero’ tariffs on medtech with all key trading partners.”
Related Reading
Resource / Coverage & Payment / Emerging Policy Response Resources / Global & Trade / Supply Chain / Tariffs
Supreme Court’s Decision in Kennedy v. Braidwood Management, Inc.
July 2, 2025
Explore the impact of the Supreme Court’s decision in Kennedy v. Braidwood on the ACA preventive services mandate and its implications for MedTech policy.
Resource / Emerging Policy Response Resources / Tariffs
Tariff-related Litigation Update – 6/27
June 30, 2025
Member-only overview of IEEPA reciprocal & “fentanyl” tariffs under EO 14257, summarizing key federal court challenges and rulings through June 17, 2025.
Blog / Diabetes / Diagnostics / Digital Health / Government & Legislative Affairs / Medical Imaging / Orthopedic / Radiation Therapy
Medtech Goes to Capitol Hill
June 26, 2025
AdvaMed’s annual Medtech Showcase and Reception on Capitol Hill seeks to inform a core audience: the members of the Congress and their staff who enact the policies that help our member companies reach patients with their transformative medtech.
Resource / Emerging Policy Response Resources / Tariffs
Tariff-related Litigation Update – 6/20
June 20, 2025
Member-only summary of IEEPA “fentanyl” and reciprocal tariffs under EO 14257, plus status of related legal challenges across federal courts through June 17, 2025.
Resource / Emerging Policy Response Resources / Tariffs
Tariff-related Litigation Update
June 16, 2025
Explore the latest IEEPA tariff developments and legal challenges, including executive orders on fentanyl tariffs and reciprocal duties affecting global MedTech trade.
Blog / Global & Trade / Government & Legislative Affairs / Regulatory Affairs / Tariffs
Medtech is Essential: Industry Supports Call for Tariff Flexibility
May 29, 2025
AdvaMed President and CEO Scott Whitaker testified before the U.S. Senate Finance Committee, bringing attention to the pressing issue of how tariffs could impact the medtech industry and, most importantly, the patients who depend on it.
Event / Emerging Policy Response Resources / Global & Trade / Government & Legislative Affairs / Supply Chain / Tariffs
URGENT: Court Ruling on Tariffs — Implications for Medtech
Now On Demand!
Emergency Briefing on Court Ruling on Tariffs and Its Impact on Medtech. Now On Demand!
News / Business Development / Government & Legislative Affairs / Small Business
AdvaMed Welcomes Introduction of American Innovation and Jobs Act
May 22, 2025
WASHINGTON—AdvaMed, the Medtech Association, welcomed introduction of the bipartisan Access to Prescription Digital Therapeutics Act of 2025 (S. 1702/H.R. 3288) by U.S. Sens. Shelley Moore Capito (R-W.Va.) and Jeanne Shaheen (D-N.H.) and U.S. Reps. Kevin Hern (R-Okla.) and Mike Thompson (D-Calif.). The bill provides for Medicare and Medicaid coverage of evidence-based software applications used to prevent, manage, or treat medical conditions.